BioSpace News Archive

ReNeuron Group plc announced that it has signed a new research evaluation agreement with a major U.S. biotechnology company in connection with the use of the Company’s proprietary exosomes for the delivery of novel gene silencing therapeutics.

Many respondents indicate feeling stressed most of the time, citing family welfare, long-term financial futures, and job prospects as primary causes.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced the first patient has been dosed at The University of Texas MD Anderson Cancer Center in the Phase 1b/2a clinical trial of NT-I7 in combination with KEYTRUDA®, a leading checkpoint inhibitor, for the treatment of patients with relapsed/refractory advanced solid tumors.

Aquablation Therapy Clinical Trial and Real-World Data Highlight Sustained Durability, Safety and Preservation of Sexual Function for a Broad Range of BPH Patients

Rite Aid Corporation announced that it has commenced an exchange offer to Eligible Holders for up to $750 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2023 for newly issued 8.000% Senior Secured Notes due 2026 and cash, upon the terms and subject to the conditions set forth in the offering memorandum and consent solicitation statement dated June 25, 2020.

Edge Pharma has signed an agreement with ANI Pharmaceuticals to market the company’s FDA approved Vancomycin Hydrochloride for Oral Solution USP, a generic equivalent to Vancocin®.

Tris Pharma, Inc., a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the launch of a new corporate website that better embodies the company’s evolving business model and strategic goals.

AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds Reduction in fibrosis was observed from single AIV001 treatment post-wounding NEWPORT BEACH, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced completion of its first Phase 1/2a study evaluating AIV001 in dermal scarring. A total of 16 subjects who

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the initiation of a Phase 2 trial of its potent, second-generation core inhibitor, ABI-H2158 (2158). The international multi-center, randomized, placebo-controlled trial will evaluate 2158 with entecavir versus placebo with

Next-Generation Technology Makes Percept™ the First and Only DBS System with Ability to Capture Patient-Specific Brain Signals for More Personalized, Data-Driven Treatment DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announces it received Food and Drug Administration (FDA) approval for the Percept™ PC Deep Brain Stimulation (DBS) system. BrainSense™ technology makes Percept the first and only DBS neurostimulation sys